Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 30, 2013)
-
Targacept Completes Recruitment in Phase 2b Trial of TC-1734 in Mild to Moderate Alzheimer’s DiseaseBusiness Wire (Apr 29, 2013)
-
-
Business Wire (Apr 22, 2013)
-
Business Wire (Apr 18, 2013)
-
-
Insiders Are Buying These 4 Cash Rich CompaniesKapitall • Sun, Apr 7
-
Business Wire (Mar 18, 2013)
-
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 26, 2013)
-
Business Wire (Feb 13, 2013)
-
Business Wire (Feb 6, 2013)
-
Business Wire (Feb 4, 2013)
-
BioLine Is Approaching Its Moment Of TruthBioassociate Consulting • Mon, Dec 3, 2012 -
Business Wire (Nov 27, 2012)
-
Business Wire (Nov 15, 2012)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
Targacept's Depressing Plunge As Antidepressant FailsDerek Lowe • Wed, Nov 9, 2011 -
Targacept: Ready to Take OffJason Chew • Mon, Jun 21, 2010 -
Expect Targacept to Move HigherDan Rosenblum • Wed, Oct 21, 2009 -
Tiny Targacept Experiences Unusual Volume SurgeH.S. Ayoub • Wed, Apr 18, 2007
-
-
-
Insiders Are Buying These 4 Cash Rich CompaniesKapitall • Sun, Apr 7
-
-
BioLine Is Approaching Its Moment Of TruthBioassociate Consulting • Mon, Dec 3, 2012
-
-
-
-
-
-
-
-
-
Tracking Seth Klarman's Baupost Group Holdings: Q1 2012 UpdateJohn Vincent • Mon, May 14, 2012 -
-
-
-
-
Tuesday Options RecapFrederic Ruffy • Tue, Mar 20, 2012 -
-
Targacept Q4 2009 Earnings Call TranscriptFri, Feb 12, 2010
-
Targacept, Inc. Q3 2009 Earnings Call TranscriptThu, Nov 5, 2009
-
Targacept, Inc. Q2 2009 Earnings Call TranscriptWed, Aug 5, 2009
-
Targacept, Inc. Q4 2008 Earnings Call TranscriptThu, Feb 12, 2009
-
Targacept, Inc. Q3 2008 Earnings Call TranscriptThu, Nov 20, 2008
-
Targacept, Inc Q2 2008 Earnings Call TranscriptTue, Aug 5, 2008
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 30, 2013)
-
Targacept Completes Recruitment in Phase 2b Trial of TC-1734 in Mild to Moderate Alzheimer’s DiseaseBusiness Wire (Apr 29, 2013)
-
Business Wire (Apr 22, 2013)
-
Business Wire (Apr 18, 2013)
-
Business Wire (Mar 18, 2013)
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 26, 2013)
-
Business Wire (Feb 13, 2013)
-
Business Wire (Feb 6, 2013)
-
Business Wire (Feb 4, 2013)
-
Business Wire (Nov 27, 2012)
-
Business Wire (Nov 15, 2012)
-
Business Wire (Nov 6, 2012)
-
Business Wire (Nov 1, 2012)
-
Business Wire (Oct 11, 2012)
-
Business Wire (Oct 8, 2012)
-
at MarketWatch.com (Sep 18, 2012)
-
Business Wire (Sep 17, 2012)
-
Business Wire (Sep 5, 2012)
TRGT vs. ETF Alternatives
Company Description
We are a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics™, a new class of drugs for the treatment of diseases and disorders of the central nervous system. Our NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found... More
